

Shuwen Biotech and Stella Maris Medical Alerts LDA Announce Partnership to Commercialize Uromonitor® in China

DEQING, CHINA, June 1, 2021 /EINPresswire.com/ -- [Shuwen](#) Biotech, a China-based integrated in vitro diagnostics company and Stella Maris Medical Alerts LDA, today announced a partnership between the two companies for commercializing in China Uromonitor®, a proprietary molecular test for detecting bladder cancer and monitoring bladder cancer recurrence through a non-invasive method.



Uromonitor® also adds to our growing portfolio of cancer testing products.”

Jay Z. Zhang

Under the terms of the agreement, Shuwen will distribute Uromonitor® and offer testing services with Uromonitor® in its CAP-accredited clinical labs in China.

Uromonitor® is a CE-certified novel urine-based test for

non-muscle invasive bladder cancer. It can be used for detecting the tumor in patients under recurrence surveillance or suspected of bladder cancer (e.g. hematuria), ancillary to cystoscopy and urine cytology. It has been validated in multicenter studies and exhibits high sensitivity and specificity.

“We are pleased to take on Uromonitor® in China to offer bladder cancer patients and their physicians an innovative and accurate test for early diagnosis and early detection of cancer recurrence,” commented Jay Z. Zhang, Chairman and CEO of [Shuwen Biotech](#). “Uromonitor® also adds to our growing portfolio of cancer testing products. And this partnership is another step towards our goal of benefiting patients with a full menu of the most innovative diagnostic tests for disease prevention, diagnosis and personalized treatment.”

André Caldeira, VP of Stella Maris Medical Alerts, commented: “We are pleased to partner with Shuwen, a leading innovative diagnostic company in China. The collaboration with Shuwen provides us access to the Chinese market allowing Uromonitor® to benefit Chinese patients. We hope that in the near future we will be able to drastically reduce cystoscopies in China.”

About Shuwen Biotech

Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and

commercial institutions to commercialize first-in-class diagnostic technologies and patents and has developed a range of novel diagnostics in the fields of cancer and women's health. Shuwen has also developed quality companion diagnostics and provided central lab biomarker testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.

For more information, please contact

Jay Z. Zhang
Shuwen Biotech
info@shuwendx.com

This press release can be viewed online at: <https://www.einpresswire.com/article/542621840>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.